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Purpose: Belimumab is an approved therapy for the
treatment of systemic lupus erythematosus (SLE). This
study examined the real-world utilization patterns of
belimumab and standard SLE therapies in patients after
regulatory approval of belimumab in the United States.
Methods: A retrospective, observational study of
belimumab users in the HealthCore Integrated Re-
search Database was conducted using administrative
claims data (GlaxoSmithKline Clinical Study Register
Study ID: 114955). The overall population for anal-
ysis was composed of patients who were prescribed
belimumab, had Z6 months pre- and Z6 months
post-index medical and pharmacy eligibility, and at
least 1 medical claim for SLE. Patients’ clinical and
demographic characteristics, treatment history, treat-
ment patterns of belimumab, utilization of other
medications, all-cause resource utilization, and costs
were assessed. No hypotheses were tested.
Findings: All patients who were prescribed
belimumab had an SLE claim. Patients who met all
eligibility criteria (n ¼ 155) were primarily female
(94.2%; mean [SD] age, 44 [12] years) and 94.2%
had used standard SLE therapies during the pre- and
post-index periods. The majority had moderate SLE
disease severity pre-index, and there was a small shift
(approximately 8%) from moderate to mild SLE after
initiation of belimumab. Two thirds of patients re-
mained on belimumab therapy at 6 months post-index.
The percentage of patients with any claim for oral
corticosteroids remained stable; however, the point
estimate for mean daily dose decreased slightly in
months 3 to 6 post-index. Inpatient hospital admissions*Current afﬁliation: Takeda Pharmaceuticals U.S.A., Inc.,
Deerﬁeld, IL, USA (D.F.E.L.); Viiv Healthcare, RTP, NC, USA
(A.O.); Amgen, Thousand Oaks, CA, USA (J.P.); Center for
Population Health IT, Johns Hopkins University, Baltimore,
MD (H.K.); Center for Observational and Real-world
Evidence (CORE), Merck, North Wales, PA (R.B.).
2852decreased slightly in the post-index period. The point
estimate for total costs (excluding belimumab) de-
creased after initiation of belimumab, although overall
total health care costs (including belimumab) increased.
Implications: All patients with a belimumab pre-
scription had an SLE diagnosis on at least 1 medical
claim, and the vast majority of those meeting all
eligibility criteria had previously used a standard
SLE therapy. Disease severity improved for a number
of patients while on belimumab treatment and modest
corticosteroid dose reductions were observed in later
months. After initiating belimumab, health care costs
(excluding belimumab) decreased. GlaxoSmithKline
Clinical Study Register Study ID: 114955. (Clin Ther.
2015;37:2852–2863) & 2015 The Authors. Published
by Elsevier HS Journals, Inc.
Key words: belimumab, real world, systemic lupus
erythematosus, utilization patterns.INTRODUCTION
Systemic lupus erythematosus (SLE) is a chronic
autoimmune disease that can result in organ damage,
negatively affects health-related quality of life, and is
associated with increased mortality.1–4 In many pa-
tients with SLE, there is overexpression of the cytokine
B lymphocyte stimulator, which is a major factor in
the selection and survival of B cells.5 Elevated
circulating cytokine B lymphocyte stimulator levels
are associated with increased disease activity and
autoantibody concentrations.5–7
Belimumab is a human immunoglobulin G1λ
(IgG1λ) monoclonal antibody that binds to andAccepted for publication October 5, 2015.
http://dx.doi.org/10.1016/j.clinthera.2015.10.008
0149-2918/$ - see front matter
& 2015 The Authors. Published by Elsevier HS Journals, Inc. This is an
open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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X. Ke et al.inhibits the activity of cytokine B lymphocyte stim-
ulator.8 The clinical efﬁcacy of belimumab was
reported in the BLISS Phase III clinical trials (BLISS-
76 [ClinicalTrials.gov identiﬁer: NCT00410384] and
BLISS-52 [ClinicalTrials.gov identiﬁer: NCT004
24476]).9,10 In March 2011, belimumab was
approved for the treatment of moderate to severe
SLE for patients with active autoantibody-positive
SLE receiving standard therapy, and was the ﬁrst
new drug approved for SLE in >50 years.11,12
The objectives of the present retrospective observa-
tional study were to describe the clinical and demo-
graphic characteristics of patients receiving belimumab,
including treatment history within the 6 months before
initiation of belimumab; medication treatment patterns
of belimumab (compliance and discontinuation) and the
use of other standard lupus therapies after belimumab
initiation; and all-cause resource use and costs pre- and
post-belimumab initiation among patients initiating
belimumab during the ﬁrst 17 months after US Food
and Drug Administration approval.
METHODS
Study Design and Population
This study (GHO-11-3501/GSK114955) was a
retrospective, observational cohort study of newly
initiated belimumab users in the United States that
examined claims data from the HealthCore Integrated
Research Database. IRB approval was not required, as
this was an observational, noninterventional, admin-
istrative claims data analysis. The study was con-
ducted in accordance with the appropriate researchStudy intake p
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Figure 1. Study design.
December 2015guidelines, such as the Good Pharmacoepidemiology
Practices issued by the International Society for
Pharmacoepidemiology. Patients with at least 1 insur-
ance claim for belimumab (medical claims with
belimumab-speciﬁc Current Procedural Terminology
codes Q2044 or J0490, or pharmacy claims with
Generic Product Identiﬁers 99422015002120 or
99422015002140) were identiﬁed during an intake
period between March 1, 2011 and July 31, 2012.
The index date was deﬁned as the date within the
intake period of the ﬁrst insurance claim for belimu-
mab (Figure 1). Medical, pharmacy, and eligibility
data from between September 1, 2010 and January
31, 2013 (study period) were collected (Figure 1).
Patients who had at least 1 medical or pharmacy claim
for belimumab, Z6 months pre- and Z6 months
post-index continuous medical and pharmacy eligi-
bility (ie, continuous insurance coverage for this
period), and at least 1 medical claim for SLE during
the 6-month pre-index period or 6-month post-index
period were selected for the ﬁnal analysis (overall
population). Patients were followed until loss of
insurance eligibility or the end of the study period,
whichever occurred ﬁrst.
Study Assessments
Age and gender of participants were recorded at the
index date. As validated clinical measures of SLE
disease activity were not available in the database, the
severity of SLE during the 6-month pre-index period
and 6-month post-index period was determined using a
previously published claims-based algorithm that waseriod
te
aim for
b)
 eligibility data
≥6 months post-index eligibility
3102/13/10
07/31/2012
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Clinical Therapeuticsdeveloped using information from the literature and
clinical consultations.13 Patients were categorized as
having mild, moderate, or severe SLE disease activity.
The patient’s overall condition was measured by
the Deyo-Charlson Comorbidity Index both pre- and
post-index.14,15 In addition, SLE-speciﬁc comor-
bidities16 and other comorbidities, determined by the
International Classiﬁcation of Diseases, Ninth Revision
codes in medical claims, were recorded. Prescribed SLE
medications included corticosteroids, antimalarials, and
immunosuppressants. The number of patients who
received prescribed SLE medications and the mean
daily doses in the 6-month pre-index and 6-month
post-index period were recorded by month for the
overall population (patients meeting all inclusion
criteria) and the subset of patients who remained on
belimumab for at least 6 months. Treatment patterns
were assessed by the number of patients who discon-
tinued belimumab therapy (>105 days between 2
administrations) and the number of patients who
complied (r45 days between consecutive administra-
tions [dosing interval multiplied by 1.5]) with treat-
ment. In calculating discontinuations occurring >6
months after initiating belimumab, standard survival
analysis techniques were used to account for censored
data. All-cause health care resource utilization was
based on the prevalence and the number of unique
health care encounters during the speciﬁed time period.
Resource use and health care costs were stratiﬁed by
medical encounters (physician ofﬁce visits [ofﬁce eval-
uation and management services], emergency depart-
ment visits, other outpatient services [all encounters not
belonging to physician ofﬁce visits, for example inpa-
tient or emergency department visits, including claims
reported as outpatient hospital visits, laboratory, ur-
gent care, outpatient other facility, or ofﬁce and clinic
visits without Current Procedural Terminology codes
shown as evaluation and management], inpatient hos-
pitalizations) and pharmacy dispensing. Health care
costs were reported as total costs across all resources
(medical and pharmacy) and the combined amount
paid by both the health plan and the patient; values
were adjusted to 2013 US dollars based on the most
recent medical care price index information provided
by the Bureau of Labor Statistics at the time of analysis.
Data Analyses
The primary analyses were carried out on the overall
population (as deﬁned here). The study was descriptive2854and no formal comparison or hypothesis testing was
performed. Descriptive statistics included mean (SD) and
median, range, and relative frequency for continuous
and categorical data, respectively. Concomitant medica-
tions were examined for the overall population and for a
subgroup of patients who remained on belimumab
treatment for at least 6 months. Mean daily doses of
concomitant medications were calculated from strength
quantity dispensed/days of supply; prednisone-equivalent
doses were calculated for corticosteroids.
RESULTS
Clinical and Demographic Characteristics of
Patients Receiving Belimumab
Among approximately 18.5 million patients in the
database who had at least 1 day of medical and
pharmacy eligibility during the study period, there
were 36,326 patients with at least 1 claim for SLE and
265 patients with a belimumab claim during the study
period. All patients with a belimumab claim also had
at least 1 medical claim for SLE. A total of 155
patients met all the eligibility requirements (at least 1
insurance claim for belimumab, at least 1 medical
claim with a diagnosis code for SLE, and Z6 months
pre- and Z6 months post-index insurance coverage)
and were included in the ﬁnal analysis (Table).
The patient population was primarily female
(94.2%) with a mean age of 44 years. The majority
of patients had moderate SLE and there was a small
shift (approximately 8%) from moderate to mild SLE
severity in the 6-month post-index period, while the
proportion of patients with severe SLE had no
appreciable change. Mean and median follow-up
times of continuous post-index eligibility (medical
and pharmacy) were 383 and 372 days, respectively
(quartile 1: 255 days; quartile 3: 507 days; maximum,
651 days). The mean Deyo-Charlson Comorbidity
Index increased from 1.46 (pre-index) to 1.85 (post-
index), indicating an increasing comorbidity burden.
During both the pre- and post-index 6-month periods,
the most common SLE-related comorbidities were
cardiac disease, hypertension, rheumatoid arthritis
(RA) or other inﬂammatory polyarthropathies, and
myositis. In the pre-index period, 17.4% of patients
had at least 2 claims for RA.
Belimumab Treatment Patterns Postinitiation
By 12 months post-index, 54.8% of patients
remained on belimumab and at 18 months more thanVolume 37 Number 12
Table. Demographics, disease severity, and
possible comorbidities.
Data are given as percentages unless
otherwise noted.
Patient Characteristics
Pre-
index
Post-
index
n 155 155
Female 94.2 
Age, y, mean (SD) 44
(12)

SLE severity*
Severe 16.1 16.8
Moderate 66.5 58.1
Mild 17.4 25.2
SLE-related comorbidities in Z7.5% of patients
(pre-index)†
Anxiety 9.7 7.7
Depression 12.3 18.7
Nephritis 7.7 8.4
Renal disease 9.7 10.3
Cardiac disease 36.1 29.7
Hypertension 29.0 30.3
Rheumatoid arthritis 27.1 27.7
Osteoporosis 11.0 16.8
Myositis 25.2 24.5
Rash 8.4 4.5
Anemia 10.3 12.9
Raynaud syndrome 11.0 7.7
NonSLE-related comorbidities in Z7.5% of
patients (pre-index)†
Diabetes mellitus 11.0 9.7
Depression (other than major
depressive disorder)
8.4 12.9
Urinary tract infection 14.8 11.6
SLE, systemic lupus erythematosus.
*Severity determined using a claims-based algorithm
published previously.13
†Percentages for patients with at least 1 claim.
X. Ke et al.half of patients were still using belimumab (50.8%)
(Figure 2). Approximately 7.1% of 155 patients
discontinued belimumab after just one infusion.
Most treatment withdrawals occurred in the ﬁrst 6
months post-index and 66.5% of patients remained
on therapy at 6 months post-index. During the entireDecember 2015post-index period, 43.2% of patients discontinued.
A high percentage (90.3%) of patients had at least
1 episode of compliant administration (r45 days
between consecutive administrations) of belimumab
and 47.7% of patients had noncompliant admini-
stration (>45 days and r105 days between
consecutive administrations).
Prior and Concomitant Utilization of Standard
Therapies for SLE
In this study, 94.2% of patients used a standard
SLE therapy (corticosteroid, immunosuppressant,
antimalarial) at some time during the 6-month pre-
index and 6-month post-index period (Figure 3).
The most common combination was antimalarials
plus oral corticosteroids plus immunosuppressants
(29.0% and 25.2% of patients pre- and post-index,
respectively).
Pre-index, 66.5% of patients had a claim for oral
corticosteroids with an estimated mean oral
prednisone-equivalent daily dose of 17.6 mg among
those on oral corticosteroids. The percentage of
patients with a claim for oral corticosteroids remained
in a stable range in both the overall population and
among patients who received belimumab for at least 6
months, with some increase in the months immedi-
ately after the ﬁrst belimumab infusion (Figure 4).
Oral prednisone-equivalent daily dose, for patients
prescribed corticosteroids initially, declined in the pre-
index period but increased as the index date ap-
proached for both the overall population and patients
who were on belimumab for at least 6 months
(Figure 5). Post-index mean oral prednisone-
equivalent daily dose tended to increase in months
12 and decrease thereafter. For patients who started
oral corticosteroids within the pre-index period and
did not discontinue before index (n ¼ 42), 21
discontinued oral corticosteroids in post-index month
1, and 39 discontinued by post-index month 6.
The percentage of the overall population using oral
immunosuppressant therapies was within a stable range
from pre-index month 6 (35.5%–40.7% across all pre-
index time points) to post-index month 6 (36.1%–39.4%
across all post-index time points). Among patients who
were on belimumab for at least 6 months, use of oral
immunosuppressants was generally stable before belimu-
mab initiation (36.9%–44.7% across all pre-index time
points), but appeared to decline slightly from month 3
(39.8%) to month 6 (35.0%) post-index. The mean daily2855
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Figure 2. Time from belimumab initiation to discontinuation or censoring for all patients (n ¼ 155).
Clinical Therapeuticsdose of immunosuppressant among patients prescribed
immunosuppressants in the overall population increased
as the index date approached (from 556.7 mg at pre-
index month 6 to 745.5 mg at pre-index month 1). There
was a similar pattern among patients who were on
belimumab for at least 6 months (494.0 mg at pre-index
month 6 increasing to 690.7 mg at pre-index month 1).
Post-index, the mean daily dose tended to decrease
slightly (post-index month 2: overall population,
658.4 mg; patients on belimumab for at least 6 months,
659.5 mg) and then increased later in the post-index
period (post-index month 6: overall population, 732.1 mg;
patients on belimumab for at least 6 months, 777.4 mg).
Among patients prescribed oral antimalarials, use
remained stable in the overall population (52.9%
60.0% pre-index; 52.9%58.1% post-index) and
among patients on belimumab for 6 months
(52.4%59.2% pre-index; 51.5%58.3% post-
index). The mean daily dose of oral antimalarials in
the overall population (382.6392.9 mg pre-index;
380.0385.1 mg post-index) and among patients on
belimumab for 6 months (390.2398.8 mg pre-index;
382.2386.4 mg post-index) was also stable pre- and
post-index.All-Cause Resource Use and Costs Pre- and
Post-belimumab Initiation
Inpatient hospital admissions decreased slightly from
20.0% (31 patients) pre-index to 17.4% (27 patients)2856post-index (Figure 6A). Both the mean number of
physician ofﬁce visits and other outpatient visits
increased post-index versus pre-index (Figure 6B).
Post-index, excluding belimumab, the cost of in-
patient admissions, emergency department visits, and
outpatient services decreased. Pharmacy costs re-
mained very similar, while the cost of physician ofﬁce
visits increased slightly. Overall total costs, excluding
belimumab, decreased pre- to post-index. However,
total costs including belimumab increased from pre- to
post-index (Figure 6C).DISCUSSION
This is the ﬁrst study to describe the real-world
treatment patterns of belimumab in patients with
SLE and explore its impact on the utilization of
standard SLE therapies and all-cause health care
resource utilization and costs.
The study population demographics were similar to
those of the BLISS-76 trial (conducted in 19 countries
in Europe and North and Central America),9 the
BLISS-52 trial (conducted in 13 countries in Latin
America, Asia-Paciﬁc, and Eastern Europe),10 and the
OBSErve study (a medical chart review of US patients
with SLE that examined the clinical effectiveness of
adding belimumab to standard SLE therapies for at
least 6 months).17 In the present study, a majority of
the population were estimated to have moderate SLE.
After belimumab treatment, a small proportion ofVolume 37 Number 12
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Figure 3. Percentage of patients using standard therapies for systemic lupus erythematosus in the pre-index
(A) and post-index (B) periods.
Corticosteroids (betamethasone, budesonide, cortisone, desoxycorticosterone, dexamethasone,
fludrocortisone, hydrocortisone, methylprednisolone, paramethasone, prednisolone, prednisone,
triamcinolone), antimalarials (artemether-lumefantrine, atovaquone-proguanil, chloroquine, halo-
fantrine, hydroxychloroquine, mefloquine, primaquine, pyrimethamine, quinacrine, quinine, sulfa-
doxine and pyrimethamine, chloroquine, and primaquine), and immunosuppressants (azathioprine,
methotrexate, cyclophosphamide, mycophenolate mofetil, and chlorambucil).
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Clinical Therapeuticspatients (approximately 8%) reported improved
disease severity from moderate to mild.
A high number of RA claims were recorded in this
study, pre- and post-index; 27.7% of patients had at
least 1 post-index RA claim, despite being treated with
belimumab, which possibly indicates a coding issue.
Overlap between RA and SLE can occur, although it is
not thought to be common; 1 study of medical records
found SLE features in 15.5% of patients with RA over
25 years.18 This is somewhat lower than the overlap
in the present analysis, further suggesting the
possibility of a coding issue. The reasons for this
coding issue are unknown, but the high number of RA
claims may be due to payers’ expectation of an RA
code for certain tests and physicians’ consequent use
of this particular code to ensure reimbursement.
The recommended dosing regimen for belimumab
is 10 mg/kg on days 0, 14, and 28, and at 4-weekly
intervals thereafter.12 In the real world, patients might
not be able to adhere to the monthly dosing schedule
due to time constraints through work, family, or other
commitments. Based on the criterion of r45 days
for compliant administration, a high percentage
of patients (approximately 90%) had at least 12858compliant administration of belimumab. However,
>40% of patients had at least 1 instance of
noncompliance, which might have had an impact on
efﬁcacy. The pattern of belimumab use found that
most treatment withdrawals occurred in the ﬁrst 6
months of treatment, which might not be sufﬁcient
time to adequately assess the efﬁcacy of belimumab.
The majority of patients (94.2%) used a standard
therapy at some point during the 6-month pre-index
and 6-month post-index period. The monthly use of
oral corticosteroids in the 6-month pre-index period
ranged from 39.4% to 46.5% of patients and is
comparable with the percentages of patients taking
oral corticosteroids (>7.5 mg/d at baseline; 44.0%
48.0%) in the BLISS-76 trial.10 However, in the
OBSErve study and BLISS-52 trial, 78.7% and
69.4% of patients, respectively, were taking oral
corticosteroids (>7.5 mg/d in the case of the BLISS-
52 trial) at baseline.10,17 During the ﬁrst 6 months on
belimumab, the percentage of patients using oral
corticosteroids in the present study remained stable.
However, the mean daily dose increased slightly in
months 1 to 2 post-index, and then subsequently
dropped in the later post-index period (3 to 6 months),Volume 37 Number 12
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Figure 5. Mean prednisone equivalent daily dose of oral corticosteroids in the overall population (A) and
among patients using belimumab for at least 6 months (B).
n, number of patients receiving oral corticosteroids at each time point.
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Clinical Therapeuticswhich could indicate a potential decrease in cortico-
steroid dose with the use of belimumab, as
was observed in the BLISS-52 trial.10 However,
speculation is limited by the fact that an insurance
claim might not necessarily indicate corticosteroid use
in this study, whereas in the BLISS trials and OBSErve2860study, the dose of corticosteroids taken by patients
was recorded by the physician.9,10,17 In the BLISS
trials and OBSErve study, the mean daily oral cortico-
steroid dose decreased steadily over time, although
a signiﬁcant change was only found in BLISS-52,
which might reﬂect treatment patterns in non-USVolume 37 Number 12
X. Ke et al.countries.9,10,17 In the BLISS trials, changes in cortico-
steroid dose were controlled in part by the study
protocol9,10; observational studies such as this, which
measure real-world outcomes, are important for the
understanding of treatment patterns.
In this study, the relatively constant proportion of
patients on corticosteroids, and the small increase in
dose in the early post-index period, might be due to
some initial caution among physicians prescribing
belimumab for the ﬁrst time. Anecdotal evidence
suggests that some physicians might want their pa-
tients to have corticosteroids available to treat acute
SLE symptoms during times of ﬂare, and might have
verbally advised them to increase or decrease their
dose as needed. Alternatively, belimumab could have
been initiated during an SLE ﬂare and treating
physicians might have felt the need to treat the ﬂare
with corticosteroids, given that the effectiveness of
belimumab is thought to increase slowly during the
ﬁrst few months after therapy initiation.9,10 The
percentages of patients using oral immunosuppres-
sants and antimalarials were generally comparable
with those in the BLISS trials.9,10
This study suggested there was a small drop in the
number of hospitalizations with a small reduction in
associated costs. There was a slight increase in
physician ofﬁce visits, which was likely due to patients
receiving belimumab infusions in the physician’s
ofﬁce. Costs for patients receiving belimumab were
relatively large and included in-pharmacy claims and
other outpatient claims, probably due to infusion
visits. After the initiation of belimumab, as expected,
overall total costs increased, mainly due to the costs
associated with belimumab. However, total costs
excluding belimumab decreased slightly, primarily
driven by the decrease in inpatient admissions cost
and other outpatient services.
There are several limitations of the study. First,
claims data may not give a complete picture of the
actual treatments and doses taken by the patient,
providing only data on those who ﬁlled a prescription
that resulted in a processed insurance claim and
providing no information on the safety of belimumab.
Second, the presence of a diagnosis code on a medical
claim does not guarantee positive presence of a
disease, as the diagnosis code may be incorrectly
coded or included as physicians order tests that would
rule out the hypothesized diagnosis. However, 94% of
patients in this study had evidence of receivingDecember 2015standard lupus therapies, which suggests that in the
majority of cases the SLE diagnosis was accurate.
Third, as with all claims-based analyses, the study
results may not be generalizable to the overall beli-
mumab user population because patients who have
commercial health insurance may have different char-
acteristics from those without health insurance.
Fourth, another limitation of database studies is the
lack of information on clinical measures, including
severity, level of organ involvement and laboratory
ﬁndings; thus, it was not possible to control for such
factors. A previously published algorithm was used to
measure disease severity,13 but this algorithm is not
yet validated and misclassiﬁcation of patients could
have occurred. Finally, the data presented in this study
are purely descriptive, with no formal comparisons
made between pre-index and post-index periods for
statistical signiﬁcance. It would be beneﬁcial to
compare the belimumab group against a control
group, but selecting an appropriate control group
without randomization would be challenging.
Similarly, using patients as their own controls could
be problematic, if in fact many belimumab patients
initiate therapy during an SLE ﬂare.CONCLUSIONS
The results of this claims database study reported on
the real-world use of belimumab; patients are adults
with an SLE diagnosis code on at least 1 medical
claim, and the majority had used a standard SLE
therapy in the 6-month pre-index and 6-month post-
index period. Most belimumab discontinuations
occurred in the ﬁrst 6 months of treatment, and
there was a decline in corticosteroid dose in the later
post-index period, which suggested a conservative
approach to corticosteroid use with some potential
for corticosteroid dose reduction in subsequent
months. Excluding the cost of belimumab, total
health care costs for belimumab users decreased
relative to the pre-treatment period, due to a reduc-
tion in inpatient and other outpatient costs. How-
ever, total costs that include belimumab increased
after starting treatment with belimumab. This study
is a valuable ﬁrst step in understanding the proﬁle of
patients prescribed belimumab in clinical practice
during the ﬁrst 18 months it was available, and
offers an opportunity to inform hypothesis genera-
tion for future studies.2861
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